Clinical validation of myOSLchip: A beryllium oxide optically stimulated luminescent dosimeter (OSLD) system in radiotherapy dosimetry
Abstract
In radiation oncology, inter-fractional dosimetry using optically stimulated luminescent detectors (OSLDs) ensures accurate plan delivery and patient safety. RadPro International GmbH's myOLSchip system, featuring a beryllium oxide (BeO) OSL dosimeter, reader, and eraser, was characterized and calibrated with a Varian Truebeam for in-vivo dosimetry following AAPM TG-191 guidelines. The BeO detectors demonstrated good dose linearity and repeatability across multiple exposures and erasure cycles, aligning with the manufacturer's stated accuracy and precision.
Read the paper
Related studies
- Characterization and Analysis of Porosity and Pore Structures
- Practical considerations for conducting ecotoxicity test methods with manufactured nanomaterials: what have we learnt so far?
- Dental Optical Coherence Tomography
- Radiation-shielding concrete: A review of materials, performance, and the impact of radiation on concrete properties
- Testing entanglement of annihilation photons
- Calanus finmarchicus seasonal cycle and diapause in relation to gene expression, physiology, and endogenous clocks
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.